Anticancer therapy
AssigneeStc.Unm
InventorJeffrey P. Norenberg
Life of this patent
Estimating the term…
Abstract
A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Claims9
1-47. (canceled)
A method of treating a somatostatin receptor expressing cancerous tumor in a patient in need, the method comprising administering to said patient an effective amount of a chelate-linked peptide analog of somatostatin comprising a radionuclide, wherein said peptide analog of somatostatin is Tyr3-Octreotide, said chelate is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and said radionuclide is the α particle emitter 213Bi (213Bi-DOTATOC), in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.